Hankang Adhesive Materials (Tianjin) Co., Ltd.

Recently, AusperBio announced that it has successfully completed A Series A funding round of up to $37 million. The financing was led by InnoPinnacle Fund with participation from Yuanbio Venture Capital, Hankang Capital, Qiming Venture Capital, Genesis Capital and many other well-known investors. The news caused widespread concern in the industry. AusperBio is an innovative drug development company with simultaneous operations in the United States and China, focusing on the research of First-in-class and Best-in-class autonomous targeted delivery of small nucleic acid drugs. The company owns the Med-OligoTM technology platform with independent intellectual property rights, mainly focusing on the functional cure of chronic hepatitis B and the targeted therapy of liver diseases. The funds raised in this round will be used to advance Phase II clinical trials of AusperBio's leading hepatitis B cure candidate AHB-137, as well as to explore combination treatment options and optimize manufacturing processes. In addition, the funds will be used to expand the company's other innovative product pipeline. Dr. Guofeng Cheng, co-founder and CEO of AusperBio, said, "The success of this financing once again demonstrates investors' recognition of our research results. We will step up clinical development of AHB-137 and hope that this potential cure will benefit patients around the world as soon as possible." Dr. Yang Chengyong, Co-founder and CSO of AusperBio, said, "We would like to thank our investors for their support and trust. In the future, we will continue to leverage our strengths in oligonucleotide research and development and targeted delivery technology to promote more innovative therapies to benefit patients."